Market Overview

ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference


(NASDAQ:IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that the Company will present at the upcoming Canaccord
Genuity Growth Conference. The presentation is scheduled for 8:30 a.m.
ET on August 8, 2018.

A webcast of the presentation will be accessible live through the
"Investors" section of the Company's website,;
a replay will be available in the same location for approximately two


ImmunoGen is developing the next generation of antibody-drug conjugates
(ADCs) to improve outcomes for cancer patients. By generating targeted
therapies with enhanced anti-tumor activity and favorable tolerability
profiles, we aim to disrupt the progression of cancer and offer our
patients more good days. We call this our commitment to "target a better
now." Our lead product candidate, mirvetuximab soravtansine, is in a
Phase 3 study for folate receptor alpha (FRα)-positive
platinum-resistant ovarian cancer, and in Phase 1b/2 testing in
combination regimens. Our novel IGN candidates for hematologic
malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at

View Comments and Join the Discussion!